Anti-idiotypic Patents (Class 530/387.2)
  • Patent number: 10065995
    Abstract: An object of the present invention is to provide a technique to create novel engineered protein ligands that, when immobilized through a lysine residue (its side chain ?-amino group) which allows for efficient immobilization to a carrier, show the optimum binding capacity and binding efficiency to a target molecule. The present invention provides an engineered protein having a sequence obtained by replacing all the lysine residues in Protein A, which is the most typical protein ligand, with other amino acids, and adding lysine at a terminal; and an affinity separation matrix in which such an engineered protein is immobilized on a water-insoluble carrier by reductive amination or the like. This affinity separation matrix is characterized by its high binding capacity to a target molecule even when the immobilized amount of the ligand is small.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: September 4, 2018
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata, Shunichi Taira
  • Patent number: 9945869
    Abstract: Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: April 17, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Kay-Gunnar Stubenrauch, Uwe Wessels
  • Patent number: 9284354
    Abstract: An object of the present invention is to provide novel polypeptides that are capable of binding to an immunoglobulin and have high stability against alkali. The present invention relates to proteins having the amino acid sequence of SEQ ID No:1 or 2.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: March 15, 2016
    Assignee: Kaneka Corporation
    Inventors: Shinichi Yoshida, Dai Murata, Shunichi Taira
  • Publication number: 20150132286
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 14, 2015
    Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
  • Patent number: 8992920
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 8992908
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventors: Jeffrey T.L. Smith, Leon F. Garcia-Martinez, Andrew L. Feldhaus
  • Publication number: 20150064182
    Abstract: The present invention relates to heterospecific polypeptide constructs comprising at least one single domain antibody directed against a therapeutic and/or diagnostic target and at least one single domain antibody directed against a serum protein, said construct having a prolonged lifetime in biological circulatory systems. The invention further relates to methods for stabilising VHHs in biological circulatory systems.
    Type: Application
    Filed: August 13, 2014
    Publication date: March 5, 2015
    Applicant: Ablynx N.V.
    Inventors: Karen Silence, Marc Jozef Lauwereys, Torsten Dreier
  • Patent number: 8969024
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 3, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 8961967
    Abstract: Antibody and other Fc-containing molecules with variations in the Fc region reduce binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
    Type: Grant
    Filed: November 29, 2010
    Date of Patent: February 24, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: William Strohl, Omid Vafa
  • Publication number: 20140369926
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: J. Andrew BRISTOL, Judith A. KANTOR
  • Publication number: 20140363422
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Application
    Filed: January 2, 2013
    Publication date: December 11, 2014
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
  • Publication number: 20140322244
    Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 30, 2014
    Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventor: Jennifer D. Wu
  • Publication number: 20140302517
    Abstract: Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: SOO YEON JUNG, YUN JEONG SONG, MI YOUNG CHO, HAN NA CHOI
  • Publication number: 20140271618
    Abstract: The present invention provides antibodies, as well as molecules having at least the antigen-binding portion of an antibody, recognizing a specific epitope of the protein CEACAM1 and optionally binds also other subtypes of the CEACAM protein family. Disclosed antibodies and antibody fragments are characterized by specific CDR sequences. Methods of production and use in therapy and diagnosis, of such antibodies and antibody fragments are also provided.
    Type: Application
    Filed: October 10, 2012
    Publication date: September 18, 2014
    Applicants: RAMOT AT TEL-AVIV UNIVERSITY LTD., CCAM BIOTHERAPEUTICS LTD.
    Inventors: Gal Markel, Tehila Ben Moshe, Yair Sapir, Ilana Mandel, Jacob Schachter, Rona Ortenberg
  • Publication number: 20140242068
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Application
    Filed: August 10, 2012
    Publication date: August 28, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Patent number: 8809005
    Abstract: A composition comprising a conjugate of an anti-idiotype antibody specifically binding to a CDR region of a parent antibody and method of using polyclonal human serum immunoglobulin of class E, G, M, or A, and the use of said composition as a standard in an immunoassay is presented.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: August 19, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Rudolf Vogel, Uwe Wessels
  • Publication number: 20140212408
    Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 31, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Thomas U. Hofer, Ralf Hosse, Ekkehard Moessner, Pablo Umana
  • Publication number: 20140178362
    Abstract: Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of Maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of Maba, and methods for screening agents that modulate the Maba level or activity in vivo or in vitro.
    Type: Application
    Filed: July 1, 2013
    Publication date: June 26, 2014
    Applicant: CELERA CORPORATION
    Inventors: Charles E. BIRSE, Bruno DOMON, Steve RUBEN, Candy LEE
  • Publication number: 20140170134
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).
    Type: Application
    Filed: August 15, 2012
    Publication date: June 19, 2014
    Applicant: The University of Chicago
    Inventors: Olaf Schneewind, Dominique M. Missiakas, Hwan Keun Kim, Carta Emolo, Andrea Dedent
  • Publication number: 20140170156
    Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: November 7, 2013
    Publication date: June 19, 2014
    Applicant: GENMAB A/S
    Inventors: Jessica TEELING, Paul PARREN, Ole BAADSGAARD, Debra HUDSON, Jørgen PETERSEN
  • Publication number: 20140161816
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicant: JANSSEN BIOTEHC, INC.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Publication number: 20140161798
    Abstract: The present invention provides compositions and methods for treating disorders of cholesterol and lipid metabolism by administration of an anti-PCSK9 antibody or a peptide inhibitor of PCSK9.
    Type: Application
    Filed: December 2, 2013
    Publication date: June 12, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Joseph A. Hedrick, Frederick James Monsma, Tatyana Churakova, Diane Hollenbaugh
  • Publication number: 20140134719
    Abstract: Recombinant cell surface capture proteins and detection molecules that are useful for isolating and detecting cells that produce a secreted heterodimeric protein of interest (POI) that has an immunoglobulin CH3 domain and/or substituted CH3 domain are provided. Recombinant cell surface capture proteins and detection molecules that isolate and detect bispecific antibodies are also provided. The invention also provides recombinant antigen-binding proteins that are capable of recognizing and binding to proteins of interest that contain a CH3 domain and/or a modified CH3 domain, such as a CH3 domain with or without amino acid substitutions at H95 and Y96 (IMGT).
    Type: Application
    Filed: November 14, 2013
    Publication date: May 15, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: DIPALI DESHPANDE, GANG CHEN, DARYA BURAKOV, JAMES FANDL, THOMAS ALDRICH, VISHAL KAMAT
  • Publication number: 20140127229
    Abstract: In certain embodiments, the present invention provides a method of treating an IP-10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IP-10 antibody; (b) detecting the level of the anti-IP-10 antibody in a sample of the subject; and (c) if the level of the anti-IP-10 antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IP-10 antibody in the subject such that the IP-10 related disease in the subject is treated. In certain embodiments, the present invention provides an isolated monoclonal anti-idiotypic antibody, or an antigen binding portion thereof, which binds to the anti-IP-10 antibody MDX-1100.
    Type: Application
    Filed: October 16, 2013
    Publication date: May 8, 2014
    Inventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus
  • Publication number: 20140115729
    Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 24, 2014
    Applicant: Genentech, Inc.
    Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
  • Publication number: 20140093454
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Application
    Filed: August 12, 2013
    Publication date: April 3, 2014
    Applicant: GENMAB A/S
    Inventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G.J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
  • Publication number: 20140080156
    Abstract: This invention relates to a peptide comprising or consisting of at least 8 consecutive amino acid residues of the sequence set forth in SEQ ID NO: 3, provided that said peptide does not consist of the sequence set forth in SEQ ID NO: 3, or a corresponding peptidomimetic, wherein said peptide or peptidomimetic binds to an anti-KIR4.1 antibody comprised in a sample from a patient, said patient having multiple sclerosis or a predisposition therefor, wherein preferably (i) said at least 8 consecutive amino acid residues are a subsequence of an extracellular domain of KIR4.1, said extracellular domain consisting of the sequence set forth in SEQ ID NO: 1 or 2; or (ii) said peptide comprises or consists of the sequence of SEQ ID NO: 1 or 2. The present invention furthermore relates to a method for diagnosing multiple sclerosis or a predisposition for multiple sclerosis in a subject, the method comprising determining the presence of an anti-KIR4.
    Type: Application
    Filed: May 23, 2012
    Publication date: March 20, 2014
    Applicant: Klinikum rechts der Isar der Technischen Universität München
    Inventors: Bernhard Hemmer, Rajneesh Srivastava
  • Publication number: 20140065164
    Abstract: In certain embodiments, the present invention provides a method of treating an IP10-related disease in a subject, comprising: (a) administering to the subject a predetermined dosage of an anti-IPIO antibody; (b) detecting the level of the anti-IPIO antibody in a sample of the subject; and (c) if the level of the anti-IPIO antibody from step (b) is below a threshold exposure level, increasing the dosage of the anti-IPIO antibody in the subject such that the IP-10 related disease in the subject is treated.
    Type: Application
    Filed: April 27, 2012
    Publication date: March 6, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Allison Y. Luo, Wendy L. Trigona, Jinshan Shen, Li-An Xu, Yan Zhang, Bruce Stouffer, Haibin Chen, Haichun Huang, Xiaolu Tao, Catherine Brockus
  • Publication number: 20140037628
    Abstract: The disclosure provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Application
    Filed: March 21, 2012
    Publication date: February 6, 2014
    Applicant: The United States of America, as rep., by the Secretary, Dept., of Health and Human Services.
    Inventors: Richard A. Morgan, Steven A. Rosenberg
  • Publication number: 20140038210
    Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.
    Type: Application
    Filed: February 15, 2013
    Publication date: February 6, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20140030273
    Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
    Type: Application
    Filed: February 1, 2012
    Publication date: January 30, 2014
    Applicant: GENMAB A/S
    Inventors: Sandra Verploegen, Marije Overdijk, Riemke Van Dijkhuizen, Willem Karel Bleeker, Patrick Van Berkel, Paul Parren, Steen Lisby
  • Patent number: 8637638
    Abstract: The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted in an expression vector. The chimeric proteins may be produced by introducing the expression vectors into insect cell lines. Proteins may be further purified and conjugated to a compound such as an immunogenic carrier.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: January 28, 2014
    Assignee: MMRGlobal, Inc.
    Inventors: Daniel P. Gold, Robert J. Shopes
  • Patent number: 8614297
    Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: December 24, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Essig, Wolfgang Hoesel, Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Publication number: 20130337478
    Abstract: The present disclosure relates to a method for the purification of a human IgG-CH1 domain comprising molecule using an antigen-binding protein that is capable of binding to an epitope that is comprised in the CH1 domain of each of human IgG1, human IgG2, human IgG3 and human IgG4. The disclosure further relates to the antigen-binding proteins that can be used in the method of the disclosure. The frame-work regions of the antigen-binding proteins of the invention preferably correspond to those of antibodies that naturally are devoid of light chains as may e.g. be found in camelids. The disclosure further relates to nucleic acids that encode such antigen-binding proteins, to immunoadsorbent materials that comprise such proteins, and to the uses of such immunoadsorbent materials for the purification of IgG-CH1 domain containing molecules from a variety of species.
    Type: Application
    Filed: January 31, 2012
    Publication date: December 19, 2013
    Applicant: BAC IP B.V.
    Inventors: Wilhelmus Josephus Johanna Hermans, Sven Blokland, Maria Anna van Kesteren, Johanna Magaretha Horrevoets, Franciscus Johan Marinus Detmers
  • Publication number: 20130330323
    Abstract: In vivo methods for making anti-idiotypic antibodies and compositions comprising the antibodies.
    Type: Application
    Filed: August 31, 2011
    Publication date: December 12, 2013
    Inventors: Robert J. Dunn, Marilyn R. Kehry
  • Publication number: 20130323762
    Abstract: The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid ? peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid ? peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid ? peptide.
    Type: Application
    Filed: August 7, 2013
    Publication date: December 5, 2013
    Inventors: Ulrich Essig, Wolfgang Hoesel, Kay-Gunnar Stubenrauch, Rudolf Vogel
  • Publication number: 20130315892
    Abstract: The present invention relates to the identification of 4Ig-B7-H3 protein as a tumor associated molecule that imparts protection from NK cell-mediated lysis via a 4Ig-B7-H3 receptor on NK cells. The invention provides compounds that interfere with interactions between the 4Ig-B7-H3 protein and its receptor that can be used to potentiate NK cell cytotoxicity. Also provided are compounds that bind 4Ig-B7-H3-expressing cells so as to inhibit or eliminate them. The compounds are particularly useful in the treatment of tumors, inflammatory conditions, infections and transplantation. Also provided are methods for diagnosing disease by detecting a 4Ig-B7-H3 protein.
    Type: Application
    Filed: June 7, 2013
    Publication date: November 28, 2013
    Inventors: ALESSANDRO MORETTA, ROBERTA CASTRICONI, CHRISTINA BOTTINO, LORENZO MORETTA
  • Patent number: 8592561
    Abstract: The present invention is directed to antibodies having specificity for a heavy chain class at the same time as having specificity for a first light chain. Such antibodies can be used in a method of detecting or monitoring a malignant plasma cell disease comprising determining in a sample the ratio between the relative amounts of immunoglobulins having: (i) a heavy chain class bound to ? light chains; and (ii) immunoglobulins having the same heavy chain class but bound to ? light chains.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: November 26, 2013
    Assignee: The Binding Site Group Limited
    Inventor: Arthur R. Bradwell
  • Publication number: 20130302399
    Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.
    Type: Application
    Filed: March 12, 2013
    Publication date: November 14, 2013
    Inventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan Wayne Ojala, Brian Robert Kovacevich, Katie Olson, Pei Fan, Jens Billgren, Erica Ann Stewart, Corinne C. Akatsuka, Patricia Dianne McNeill, Danielle Marie Mitchell, Dan Scott Allison, John A. Latham
  • Publication number: 20130302314
    Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP (SEQ ID NO:1) peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL (SEQ ID NO:2) and HSGQQQGLPRAAGGSVPHPR (SEQ ID NO:3), of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 14, 2013
    Inventor: Academia Sinica
  • Patent number: 8540987
    Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: September 24, 2013
    Assignees: Institute for Antibodies Co., Ltd., Japan as Represented by Director-General of National Institute of Infectious Diseases, Osaka Prefecture University Public Corporation
    Inventors: Masachika Azuma, Motohide Takahashi, Shunji Kozaki, Masafumi Mukamoto, Tomoko Kohda, Gene Kurosawa, Yoshikazu Kurosawa
  • Publication number: 20130243749
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 19, 2013
    Applicant: Dana Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Publication number: 20130231462
    Abstract: Provided are methods and compositions for immunoassays with improved sensitivity and specificity. The presently disclosed anti-immune complex antibodies stabilize the interaction between a primary and secondary antibody, thereby allowing for more stringent wash conditions, less background, and stronger signal.
    Type: Application
    Filed: February 25, 2013
    Publication date: September 5, 2013
    Applicant: Bio-Rad Laboratories, Inc.
    Inventors: Steve Roth, William Strong
  • Patent number: 8524866
    Abstract: An antibody or an antigen binding fragment thereof which binds to mammalian ?7 subunit of a nicotinic acetylcholine receptor or its functional variant and which is an agonist of said receptor or variant. Pharmaceutical compositions comprising same. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject an antibody or an antigen-binding fragment as described herein.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: September 3, 2013
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Lihong Yang, Kevin J. Tracey
  • Publication number: 20130216548
    Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
    Type: Application
    Filed: March 10, 2011
    Publication date: August 22, 2013
    Applicant: GENMAB A/S
    Inventors: Joost J. Neijssen, Bart De Goeij, Edward Norbert Van Den Brink, Aran Frank Labrijn, Rene Hoet, Janine Schuurman, Paul Parren, Jan Van De Winkel
  • Publication number: 20130209355
    Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 8, 2011
    Publication date: August 15, 2013
    Applicant: GENMAB A/S
    Inventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
  • Publication number: 20130177566
    Abstract: Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in vitro.
    Type: Application
    Filed: November 6, 2012
    Publication date: July 11, 2013
    Applicant: CELERA CORPORATION
    Inventor: Celera Corporation
  • Publication number: 20130158236
    Abstract: Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
    Type: Application
    Filed: January 5, 2012
    Publication date: June 20, 2013
    Applicant: Alexion Pharmaceuticals, Inc.
    Inventors: Katherine S. Bowdish, John McWhirter, Anke Kretz-Rommel, Toshiaki Maruyama
  • Publication number: 20130131319
    Abstract: An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above.
    Type: Application
    Filed: March 30, 2011
    Publication date: May 23, 2013
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Publication number: 20130129715
    Abstract: Use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in therapeutic and contraceptive fields The present invention concerns the use of antibodies against PLAC1 protein as biomarkers of infertility, diagnostic kit for the detection of immune response against PLAC1 and use of PLAC1 protein in tolerogenic or immunogenic form in the therapy for infertility or as contraceptive or post-coital interception means, respectively.
    Type: Application
    Filed: July 13, 2011
    Publication date: May 23, 2013
    Inventors: Arcangelo Liso, Maria Matteo